Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
-451K
-
Total reported value, excl. options
-
$37.9M
-
Value change
-
-$752K
-
Put/Call ratio
-
2.84
-
Number of buys
-
19
-
Number of sells
-
-37
-
Price
-
$1.80
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q4 2022
73 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q4 2022.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
of 56.1M outstanding shares and own 37.54% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5.4M shares), NEA Management Company, LLC (3.45M shares), RA CAPITAL MANAGEMENT, L.P. (2.59M shares), Boxer Capital, LLC (2.01M shares), Artal Group S.A. (1.65M shares), BlackRock Inc. (994K shares), CITADEL ADVISORS LLC (774K shares), VANGUARD GROUP INC (758K shares), MILLENNIUM MANAGEMENT LLC (525K shares), and Newtyn Management, LLC (315K shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.